Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Cirrhosis of liver

4,649 views

Published on

Liver Cirrhosis in a nutshell

Published in: Health & Medicine
  • Discover How to Cure Acne At Any Age, Even If You�ve Tried Everything And Nothing Has Ever Worked For You Before Click Here ●●● http://t.cn/AiWGkfAm
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here

Cirrhosis of liver

  1. 1. CIRRHOSIS OF LIVER Dr.Partha Das M.E.M. 2nd Year Fortis Hospital, Kolkata 16-05-2016
  2. 2. IMPACT OF CIRRHOSIS • 11th-leading cause of death by disease in the US • About 25,000 people die from the complications of cirrhosis/year; almost half of these are alcohol related • A/c to the latest WHO data published in may 2014 Liver Disease Deaths in India reached 216,865 or 2.44% of total deaths. (http://www.worldlifeexpectancy.com/india-liver-disease)
  3. 3. DEFINITION • Cirrhosis is defined as a diffuse process characterized by fibrosis and the conversion of normal liver architecture into structurally abnormal nodules Ref : Robbins’ & Cotran Pathologic Basis of Disease 8th Ed • Cirrhosis is a generic term for an end stage of CLD characterized by destruction of hepatocytes & replacement of normal hepatic architecture with fibrotic tissue & regenerative nodules Ref : Rosen's Emergency Medicine - Concepts and Clinical Practice 8th Ed (*kirros = orange, osis = condition – Greek)
  4. 4. Morphological Classification  Macronodular (parenchymal nodules >3mm)  Micronodular (parenchymal nodules <3mm) Etiology Frequency Chronic viral hepatitis 10-20% Wilson’s disease Rare Alpla1 antitrypsin ↓ Rare Cryptogenic Common Various drugs & toxins Rare Etiology Frequency Alcohol 60-70% Primary biliary 5% Hemochromatosis 5% Cystic fibrosis Rare
  5. 5. CAUSES OF CIRRHOSIS • Alcoholism (Laennec’s Cirrhosis) • Chronic Viral Hepatitis (Hep.B/ Hep.C) • Autoimmune Hepatitis • Biliary Cirrhosis Primary Biliary Cirrhosis Primary Sclerosing Cholangitis Autoimmune Cholangiopathy • Inherited Metabolic Liver Disease ↓alpha-1 antitrypsin Wilson’s Disease • Cardiac Cirrhosis • Cryptogenic Cirrhosis (NAFLD/NASH) • Other causes (parasitic inf, ↑ exposure to toxins)
  6. 6. PATHOGENESIS  Death of Hepatocytes  Extracellular matrix deposition  Vascular reorganization Three main characteristics of Cirrhosis :- • Involvement of most/all of the liver • Bridging fibrous septa • Parenchymal nodules of senescent & replicating hepatocytes
  7. 7. Contd… Ref : Robbins’ & Cotran Pathologic Basis of Disease 8th Ed
  8. 8. CLINICAL FEATURES & COMPLICATIONS • Fatigue • Generalized pruritus • Loss of appetite & weight • Intermittent jaundice • Loss of libido & testicular atrophy (men) • Gynecomastia • Menstrual abnormalities (females) • Bleeding tendencies (↓protein for clotting) • Ecchymoses • Edema & ascites (↓intravascular colloidal pressure & ↑capillary hydrostatic pressure) • Fetor hepaticus
  9. 9. Contd… • Asterixis (flapping hand tremors) • Portal HTN (scar tissue blocks normal flow of blood & ↑pressure in the portal vein) • GI bleed (d/t esophageal varices /hemorrhoids) • SBP (d/t long-standing ascites) • Splenomegaly (portal HTN can cause spleen to enlarge & retain WBCs & platelets) • Hepatic encephalopathy (↑accumulation of toxins like Ammonia in the brain) • Gallstones & CBD stones (d/t biliary stasis)
  10. 10. Contd… • Insulin resistance & Type 2 DM • Metabolic bone diseases • Palmar erythema • Pigmentation • Digital clubbing • Caput medusae • Spider angioma • Hepatorenal syndrome • Hepatopulmonary syndrome • Hepatic Hydrothorax • Hepatocellular carcinoma
  11. 11. LAB. EVALUATION Test category Serum measurement Hepatocyte integrity AST ↑ (AST/ALT ratio >1) ALT ↑ LDH ↑ Biliary excretory function S.Bil ↑ (total/direct) Urine Bil. ↑ S. Bile acids ↑ S. GGT ↑ S. 5-nucleotidase ↑ S.ALP ↑ Hepatocyte function S. Albumin ↓ PT ↑ S. Ammonia ↑
  12. 12. Radiological Evaluation  Ultrasound • Surface nodularity • Coarse & heterogenous echotexture • Segmental hypertrophy/atrophy • Signs of Portal HTN Enlarged p/vein (>13 mm) Slow portal venous flow (<15cm/sec) Portal vein thrombosis • Splenomegaly • Ascites • Fatty change • Cork screw appearance of hepatic arteries
  13. 13. Contd…  CT Scan • Surface nodularity (regenerative>siderotic) • Fatty change • Segmental hypertrophy/atrophy • Signs of portal HTN  MRI • Morphologic changes (same as USG & CT) • Regenerative or cirrhotic nodules
  14. 14. Other Ix  Transient Elastography (Fibro-scan) • New, non‐invasive, rapid & reproducible method • In cirrhotic patients, liver stiffness measurements range from 12.5 to 75.5 kPa  Liver Biopsy • regenerative nodules of hepatocytes surrounded by fibrous connective tissue that bridges between portal tracts • Mallory's hyaline material within hepatocytes
  15. 15. Radiological Differentials • Widespread (miliary type) liver mets • Chronic Budd-Chiari syndrome • Fulminant hepatic failure • Pseudocirrhosis • Congenital hepatic fibrosis • Hepatic sarcoidosis • Idiopathic portal HTN • Nodular regenerative hyperplasia of liver
  16. 16. Child-Pugh Score Measure 1 point 2 points 3 points T.Bil (mg/dl) <2 2-3 >3 S.Albumin (g/dl) >3.5 2.8 – 3.5 <2.8 PT <4.0 4.0 – 6.0 >6.0 Ascites None Mild Mod to Sev. Hep.Encph. None Grade I-II Grade III-IV Points Class 1 yr survival 2 yr survival 5-6 A 100% 85% 7-9 B 81% 57% 10-15 C 45% 35%
  17. 17. MELD Score • The Model for End-Stage Liver Disease, or MELD, is a scoring system for assessing the severity of CLD (e.g. Cirrhosis). • Useful in determining prognosis and prioritizing for receipt of a liver transplant. • MELD = 3.78×ln[serum Bil. (mg/dl)] + 11.2×ln[INR] + 9.6×ln[serum Creat. (mg/dl)] + 6.43 • *If the patient has been dialyzed twice within the last 7 days, then the value for serum Creat. used should be 4.0
  18. 18. Contd… • In interpreting the MELD Score in hospitalized patients, the 3 month mortality is: 40 or more 71.3% mortality 30-39 52.6% mortality 20-29 19.6% mortality 10-19 6.0% mortality <9 1.9% mortality
  19. 19. Milan Criteria • Applied as a basis for selecting patients with Cirrhosis & HCC for liver transplantation • The Milan criteria state that a patient is selected for transplantation when he or she has: • One lesion <5cm • Upto 3 lesions <3cm • No extra hepatic manifestations • No vascular invasion
  20. 20. MANAGEMENT  GENERAL MEASURES • Avoid NSAIDs (may worsen hepatotoxicity & GI bleed) • Avoid sedatives & hypnotics (may cause CNS & respiratory depression if patient is in danger of hepatic coma) • Thiamine replacement (50-100mg/day) • Iron & folate (if anemic) • BCAA supplementation (In encephalopathy) • Vit.K 10mg s/c (in case of ↑PT) • 2000-3000 calorie diet with 1g protein/kg
  21. 21. MANAGEMENT  PORTAL HTN • Pharmacologic : Beta blockers (Propranolol, Nadolol) • Endoscopic procedures : sclerotherapy and variceal ligation to prevent the recurrence of variceal bleed • Surgical care : decompressive shunts, devascularization procedures & liver transplantation.
  22. 22. Contd…  ASCITES • Water restriction (effective in dilutional ↓ Na+) • Spironolactone 100-200mg/day (monitor u/o, abdominal girth, BUN, weight) • Paracentesis (S/E transient hypovolemia, hypotension, ARF, hemoconcentration,shock) • Send ascitic fluid for lab studies (WBC count, glucose, protein, c/s, Gm stain, cytology, albumin, LDH, tumour markers)
  23. 23. Contd…  SBP Clinical setting Cirrhosis with ascites Presentation Fever, ↑abd.pain & tenderness, worsening encephalopathy Diagnosis Ascitic fluid WBC>1000/ml PMN>250/ml Treatment Ceftriaxone 2g i/v per day Piptaz 3.375g i/v 6 hourly Albumin 1.5 g/kg i/v at diagnosis and 1 g/kg i/v on 3rd day
  24. 24. Contd…  OESOPHAGEAL VARICEAL BLEED • Airway stabilization • Large-bore i/v access – Arrange PRBC & FFP • PharmacoRx Agent Dose Terlipressin 2mg 6 hourly X 1st 24 hours, 1mg 6 hourly for the 2nd 24 hours Octreotide 50mcg IV bolus, then 50mcg/hr i/v infusion Somatostatin 250–500mcg i/v bolus, then 250–500mcg/hr i/v infusion
  25. 25. Contd…  HEPATIC ENCEPHALOPATHY • Lactulose 30ml 4-6 hourly or in the form of enema P/R Stages Features I General apathy II Lethargy, drowsiness, variable orientation, asterixis III Stupor with hyper reflexia, ↑plantars IV Coma
  26. 26. REFERENCES • Rosen's Emergency Medicine - Concepts and Clinical Practice 8th Ed • Tintinalli’s Emergency Medicine 6th Ed • Robbins’ & Cotran Pathologic Basis of Disease 8th Ed • http://radiopaedia.org/articles/cirrhosis • Mudit Khanna Self Assessment & Review (Medicine) • Ferrell, Liver update on staging of Fibrosis & Cirrhosis, 2013

×